Blocking key protein could enhance multiple myeloma drug response

Blocking key protein could enhance multiple myeloma drug response

Researchers at the VIB-UGent Center for Medical Biotechnology have discovered a promising strategy to improve treatment responses in multiple myeloma patients by blocking a protein that plays a key role in drug resistance. The study, published in Pharmacological Research, offers a potential new strategy to improve outcomes for patients whose disease has become less responsive to standard therapies.

Johnson & Johnson announces successful results from trial for myeloma treatment - Pharmafile

Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed significantly longer progression-free survival (PFS) rates of newly diagnosed multiple myeloma (NDMM) than conventional bortezomib, lenalidomide and dexamethasone (VRd) chemotherapy. The treatment could help NDMM patients approach normal expectancy without their disease progressing, with PFS projected to be 17 years. […] The post Jo…